Matches in Nanopublications for { ?s ?p "[The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP186588.RAsrdDeXcxtanMmIpibdaI1NTD0kG8DfRamSSx3nKiGNY130_assertion description "[The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP186588.RAsrdDeXcxtanMmIpibdaI1NTD0kG8DfRamSSx3nKiGNY130_provenance.
- assertion description "[The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP251708.RA19TdKdUqXzsycDCRcnFw3fDz3RspwqRMIG3nEx-jMKs130_assertion description "[The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP251708.RA19TdKdUqXzsycDCRcnFw3fDz3RspwqRMIG3nEx-jMKs130_provenance.
- NP251709.RAcYaxKZbuQ35FjdADnZvpxqfZmBVq6KSPNbMRPR-3yHY130_assertion description "[The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP251709.RAcYaxKZbuQ35FjdADnZvpxqfZmBVq6KSPNbMRPR-3yHY130_provenance.
- NP251710.RARnX0OdbGPTDChcEreGGkyGOXjPnoNpQtcy0s6hHdpo8130_assertion description "[The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP251710.RARnX0OdbGPTDChcEreGGkyGOXjPnoNpQtcy0s6hHdpo8130_provenance.
- assertion description "[The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.